Articles related to METABOLIC HEALTH

Phase 3 TRIUMPH-1 trial results for retatrutide, a triple hormone agonist targeting GIP, GLP-1, and glucagon receptors, showed up to 28.3% mean weight loss at 80 weeks and 30.3% in patients with BMI ≥35 at 104 weeks — the largest weight reduction reported in a medication trial to date, per Lilly’s press release.

A narrative review of UCLA spice research found associations between common culinary spices — cinnamon, turmeric, red pepper, and spice blends — and glucose regulation, gut microbiome composition, and cognitive markers, though most findings stem from small trials and in vitro work using supratherapeutic doses.

A 2025 AACE consensus statement introduced a complication-centric, staged framework for managing adults with obesity and adiposity-based chronic disease, with drug selection tied to specific obesity-related complications rather than weight loss alone.

A 14-year international consensus effort involving 56 professional and patient organizations has renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome, a shift designed to better reflect the condition’s systemic hormonal and metabolic pathophysiology.

Bariatric surgery volumes peaked in 2022 and have fallen since, with sleeve gastrectomy losing ground and Roux-en-Y conversions climbing as GLP-1 prescriptions expand.

A systematic review of 27 studies found behavioral sleep interventions — particularly CBT-I and sleep hygiene — reduced BMI and body weight in adults with poor sleep health, with the largest effects among patients with obesity.